Phase 2 IMscin002 Study Shows Patients With NSCLC Prefer Subcutaneous Atezolizumab

Patients with non–small cell lung cancer treated on the IMscin002 trial preferred subcutaneous atezolizumab vs the intravenous formulation.

Related Keywords

Italy ,Federico Cappuzzo ,Eli Lilly ,European Lung Cancer Congress ,Pfizer ,European Commission ,Bristol Myers Squibb ,Illumina Inc ,Mirati Therapeutics Inc ,Bayer Ag ,Roche Ltd ,Astrazeneca ,Takeda Pharmaceuticals ,Amgen Inc ,Lung Cancer ,Medical Oncology ,Azienda Unit ,Sanitaria Locale ,Mirati Therapeutics ,Galecto Biotech ,Imscin002 ,Nsclc ,Non Small Cell Lung Cancer ,Atezolizumab ,Tecentriq ,Subcutaneous Atezolizumab ,Intravenous Atezolizumab ,Phase 2 Imscin002 Trial ,Felcc ,D ,Enhanze ,Azienda Unità Sanitaria Locale Della Romagna Ravenna ,